Stockscreener 앱 받기
10.11
9.34%
-1.055
전일 마감가:
$11.16
열려 있는:
$11.25
하루 거래량:
871.83K
Relative Volume:
2.78
시가총액:
$223.12M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
-52.11
EPS:
-0.1939
순현금흐름:
$-44.93M
1주 성능:
-8.02%
1개월 성능:
-7.35%
6개월 성능:
-24.98%
1년 성능:
-43.01%
1일 변동 폭
$9.95
$11.39
1주일 범위
$9.95
$13.88
52주 변동 폭
$6.50
$21.66
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
CYBN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CYBN | 10.12 | 223.12M | 0 | -52.07M | -44.93M | -0.1939 |
| VRTX | 450.00 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.18 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.92 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.91 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.24 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
HC Wainwright Has Bearish Estimate for Cybin Q3 Earnings - MarketBeat
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder - geneonline
H.C. Wainwright reiterates Buy on Cybin stock, sees strong potential for CYB003 in MDD - Investing.com
Breakthrough Therapy Shows Promising Long-Term Results for Depression - Streetwise Reports
Cybin (NYSE:CYBN) Receives Buy Rating from HC Wainwright - MarketBeat
Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report
Cybin’s CYB003 Shows Promising Results for Depression - TipRanks
Cybin reports sustained depression treatment effects - Investing.com India
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
Cybin posts second-quarter loss widens as clinical trials advance - Green Market Report
Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00 - MarketBeat
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - BioSpace
Cybin to Present Promising CYB003 Study Results - TipRanks
Cybin to Showcase Promising Depression Treatment Progress - TipRanks
Cybin Phase 3 Layout - Green Market Report
CYBNCybin Inc. Latest Stock News & Market Updates - StockTitan
Cybin Inc (CYBN-NE) QuotePress Release - The Globe and Mail
Cybin launches new program phase to treat Major Depressive Disorder | 2024-11-13 | Investing News - Stockhouse Publishing
Cybin’s Phase 3 Trials and Financial Update - TipRanks
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - StreetInsider.com
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Benzinga
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results – Company AnnouncementFT.com - Financial Times
What might RFK Jr’s psychedelic strategy look like? - Proactive Investors USA
Cybin Faces Key Data Readouts For Major Depressive Disorder, Generalized Anxiety Disorder - RTTNews
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin Inc. (NYSE:CYBN) Stake Lowered by Rosalind Advisors Inc. - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 0.2%Here's What Happened - MarketBeat
Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma
PDS Planning Inc Sells 885,540 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha
Cybin to Participate at the 2024 Milken Institute Future of Health Summit - BioSpace
Cybin to Highlight Innovations at Health Summit - TipRanks
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
(CYBN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program - MSN
Cybin secures patent for CNS disorder treatment candidates - Investing.com
Cybin announces grant of patent in support of CYB005 phenethylamines program - TipRanks
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Business Wire
$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds
Sanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin (NYSE:CYBN) Trading Down 7.4%What's Next? - MarketBeat
Cybin (NYSE:CYBN) Stock Price Up 9.7%What's Next? - MarketBeat
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha
(CYBN) Trading Signals - Stock Traders Daily
Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha
Cybin (NYSE:CYBN) Shares Gap DownWhat's Next? - MarketBeat
Cybin (OTCMKTS:CYBN) Trading 1.5% HigherHere's What Happened - MarketBeat
Cybin (NYSE:CYBN) Shares Up 5.4%Still a Buy? - MarketBeat
(CYBN) Investment Analysis and Advice - Stock Traders Daily
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):